National Bank of Canada FI Makes New $43,000 Investment in Repare Therapeutics Inc. (NASDAQ:RPTX)

National Bank of Canada FI purchased a new stake in shares of Repare Therapeutics Inc. (NASDAQ:RPTXGet Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,025 shares of the company’s stock, valued at approximately $43,000.

Several other hedge funds have also recently added to or reduced their stakes in RPTX. Millennium Management LLC lifted its holdings in Repare Therapeutics by 659.2% during the third quarter. Millennium Management LLC now owns 171,461 shares of the company’s stock valued at $4,499,000 after purchasing an additional 148,876 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Repare Therapeutics in the 3rd quarter worth $1,566,000. California State Teachers Retirement System bought a new stake in Repare Therapeutics during the third quarter valued at about $198,000. HighVista Strategies LLC purchased a new position in shares of Repare Therapeutics in the third quarter valued at about $947,000. Finally, Sectoral Asset Management Inc boosted its stake in shares of Repare Therapeutics by 25.3% in the third quarter. Sectoral Asset Management Inc now owns 516,485 shares of the company’s stock worth $13,553,000 after acquiring an additional 104,335 shares during the period. Hedge funds and other institutional investors own 69.41% of the company’s stock.

A number of brokerages have issued reports on RPTX. Zacks Investment Research lowered shares of Repare Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 5th. The Goldman Sachs Group initiated coverage on shares of Repare Therapeutics in a research note on Thursday, March 17th. They set a “buy” rating and a $43.00 target price for the company. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat.com, Repare Therapeutics currently has an average rating of “Buy” and a consensus target price of $47.29.

In other news, major shareholder Bvf Partners L. P/Il acquired 997,961 shares of Repare Therapeutics stock in a transaction that occurred on Wednesday, January 19th. The shares were bought at an average cost of $14.10 per share, with a total value of $14,071,250.10. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 33.60% of the stock is currently owned by company insiders.

Shares of NASDAQ RPTX opened at $11.24 on Monday. Repare Therapeutics Inc. has a 1-year low of $11.01 and a 1-year high of $35.75. The business’s 50 day moving average is $14.30 and its two-hundred day moving average is $19.26. The stock has a market capitalization of $470.69 million, a P/E ratio of -3.99 and a beta of 0.60.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last released its quarterly earnings results on Tuesday, March 1st. The company reported ($0.70) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.05. Repare Therapeutics had a negative return on equity of 41.95% and a negative net margin of 1,406.68%. The company had revenue of $6.88 million for the quarter, compared to analyst estimates of $3.54 million. As a group, equities analysts predict that Repare Therapeutics Inc. will post -3.58 EPS for the current year.

Repare Therapeutics Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Read More

Institutional Ownership by Quarter for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.